Company

Theratechnologies Inc.

Headquarters: Montreal, QC, Canada

Employees: 83

CEO: Mr. Paul Lévesque

TSX: TH +1.19%

Market Cap

C$86.0 Million

CAD as of July 1, 2024

US$62.6 Million

Market Cap History

Theratechnologies Inc. market capitalization over time

Evolution of Theratechnologies Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Theratechnologies Inc.

Detailed Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Theratechnologies Inc. has the following listings and related stock indices.


Stock: TSX: TH wb_incandescent

Stock: NASDAQ: THTX wb_incandescent

Stock: FSX: TQ8 wb_incandescent

Details

Headquarters:

2015 Peel Street

11th Floor

Montreal, QC H3A 1T8

Canada

Phone: 514 336 7800

Fax: 514 331 9691